National Institutes of Health consensus development conference statement: Management of hepatitis B # † ‡ п

Sorrell, Michael F.; Belongia, Edward A.; Costa, José; Gareen, Ilana F.; Grem, Jean L.; Inadomi, John M.; Kern, Earl R.; McHugh, James A. M.; Petersen, Gloria M.; Rein, Michael F.; Strader, Doris B.; Trotter, Hartwell T.

doi:10.1002/hep.22946

Cited by 128 publications

(106 citation statements)

References 1 publication

Supporting

Mentioning

106

Contrasting

Order By: Relevance

“…Almost 3% of the world's population is infected with hepatitis C virus (HCV) (1). Chronic infection with HCV may result in both hepatic and extrahepatic disease, such as inflammation of the liver, which in turn may progress to cirrhosis, liver failure or cancer (2).…”

Section: Introductionmentioning

confidence: 99%

Aberrant production of soluble inducible T-cell co-stimulator (sICOS) and soluble programmed cell death protein 1 (sPD-1) in patients with chronic hepatitis C

Wang

Zhou

et al. 2013

Molecular Medicine Reports

View full text Add to dashboard Cite

Previous studies have indicated that immune dysregulation is an important cause of HCV‑mediated damage to the liver. Co‑stimulation signals, including programmed cell death protein 1 (PD‑1) and inducible T‑cell co‑stimulator (ICOS), have been demonstrated to be involved in the pathogenesis of HCV. The purpose of this study was to investigate the soluble PD‑1 (sPD‑1) and soluble ICOS (sICOS) serum levels in chronic HCV patients, and to elucidate the association of sPD‑1 and sICOS levels with pathological injury of chronic HCV infection. Sixty‑three patients with chronic HCV and 30 normal controls were recruited for this study. The serum concentration levels of sPD‑1 and sICOS were measured by enzyme‑linked immunosorbent assay, and the mRNA levels of PD‑1 and ICOS were detected using real‑time RT‑PCR. The serum sPD‑1 and sICOS levels were significantly elevated in the chronic HCV patient group compared with the normal control group. Furthermore, the relative mRNA expression levels of these proteins were also increased in chronic HCV patients. sPD‑1 and sICOS serum levels were significantly correlated with anti‑HCV antibody levels, but not with HCV RNA. Aberrant sPD‑1 and sICOS serum levels may reflect the dysregulation of T‑cell activation, and are associated with the pathological injury of chronic HCV infection.

show abstract

Section: Introductionmentioning

confidence: 99%

Aberrant production of soluble inducible T-cell co-stimulator (sICOS) and soluble programmed cell death protein 1 (sPD-1) in patients with chronic hepatitis C

Wang

Zhou

et al. 2013

Molecular Medicine Reports

View full text Add to dashboard Cite

show abstract

“…White crystals. Yield 16%; 1 13 13 13 The crystal data of the rearranged product were shown as follows. Crystal Data for C 21 H 20 Br 2 N 2 O 2 (M =492.21): monoclinic, space group P2 1 /c (no.…”

Section: General Procedures For the Preparation Of N-(3-oxo-1-aryl-3-(mentioning

confidence: 99%

“…There are approximately 350 million chronically infected individuals, resulting in 0.5-1.2 million deaths annually [1][2][3]. Although interferon-α has been a mainstay of HBV treatment regimens, sustained response rates tend to be low (20±30%) and resistance builds rapidly [4][5].…”

Section: Introductionmentioning

confidence: 99%

Synthesis and quantitative structure–activity relationships study for phenylpropenamide derivatives as inhibitors of hepatitis B virus replication

Yang

Wang

et al. 2015

European Journal of Medicinal Chemistry

View full text Add to dashboard Cite

“…Interferon-based therapy is contraindicated and only NUCs should be used. [5,6,8,16] Treatment is indicated even if the HBV DNA level is low or undetectable, in order to prevent flares/reactivation. Treatment with NUCs may lead to clinical improvement over a period of 3 -6 months.…”

Section: Treatment Of Decompensated Cirrhosismentioning

confidence: 99%

“…[5][6][7][8][9] It serves as an attempt to contextualise practice guidelines on the management of chronic hepatitis B in SA.…”

Section: Introductionmentioning

confidence: 99%

South African guideline for the management of chronic hepatitis B: 2013

Spearman

Sonderup

Botha³

et al. 2013

S Afr Med J

View full text Add to dashboard Cite

National Institutes of Health consensus development conference statement: Management of hepatitis B # † ‡ п

Cited by 128 publications

References 1 publication

Aberrant production of soluble inducible T-cell co-stimulator (sICOS) and soluble programmed cell death protein 1 (sPD-1) in patients with chronic hepatitis C

Aberrant production of soluble inducible T-cell co-stimulator (sICOS) and soluble programmed cell death protein 1 (sPD-1) in patients with chronic hepatitis C

Synthesis and quantitative structure–activity relationships study for phenylpropenamide derivatives as inhibitors of hepatitis B virus replication

South African guideline for the management of chronic hepatitis B: 2013

Contact Info

Product

Resources

About